Phase I – III study
Ionis Heads to FDA as Antisense Therapy Aces Pivotal Study in Rare Neurological Disease
Ionis Pharmaceuticals; zilganersen; antisense oligonucleotide; Alexander disease; pivotal Phase I–III study; FDA Fast Track designation; rare neurological disease; expanded access program; walk speed improvement; Orphan Drug designation